[Inclusion body myositis].

Area of Science:

• Neurology
• Immunology
• Genetics

Context:

• Sporadic inclusion body myositis (sIBM) is a rare, progressive skeletal muscle disease characterized by chronic worsening weakness and atrophy.
• Diagnosis is often delayed, typically occurring 5 years after symptom onset, with characteristic muscle weakness in the quadriceps and finger flexors.
• Pathological hallmarks include endomysial inflammation, mononuclear cell invasion, and rimmed vacuoles, indicating coexisting inflammation and degeneration.

Purpose:

• To summarize the current understanding of sporadic inclusion body myositis (sIBM), including its clinical presentation, diagnosis, and underlying pathomechanism.
• To review the limitations of current treatments and highlight emerging therapeutic strategies for sIBM.
• To emphasize the need for further research into the etiology and pathomechanism to develop effective therapies.

Summary:

• sIBM presents with progressive muscle weakness and atrophy, often diagnosed late, with characteristic muscle biopsy findings.
• While the exact cause is unknown, genetic, aging, lifestyle, and environmental factors, along with amyloid beta accumulation and immune system abnormalities, are implicated.
• Current treatments like steroids are largely ineffective, but targeted therapies such as alemtuzumab show promise, alongside strategies to enhance proteolysis, autophagy, and muscle regeneration.

Impact:

• Improved understanding of sIBM's complex etiology and pathomechanism is crucial for developing targeted and effective treatments.
• Emerging therapeutic strategies offer hope for managing this intractable disease and improving patient outcomes.
• Further research into novel approaches like proteolysis induction, autophagy enhancement, and myostatin inhibition could lead to significant advancements in sIBM therapy.